The tradeoff: tirzepatide is newer with less long-term safety data than semaglutide, though its profile to date looks equally favorable
When to Avoid or Change Your Injection Site Do not inject into areas with visible scars, keloids, or significant skin changes because these sites have altered tissue quality and unpredictable absorption
It focuses on medicines of anemia, anxiety disorders, cancer/oncology, ear infections, heart failure, hepatitis, HIV/AIDS, influenza, non-Hodgkins lymphoma, obesity, osteoporosis, Parkinsons disease, pneumonia, transplantation, and common diseases
The FDA recommends using non-oral contraception or adding a barrier method for 4 weeks after starting tirzepatide and after each dose increase
Obesity Medicine Association